HelenaAYuMD

Instructor, Medicine, Weill Cornell Med College

Overview of Dr. Yu

Dr. Helena Yu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from University of Michigan Medical School and has been in practice 10 years. She is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(612) 293-0597
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
University of Michigan Medical SchoolClass of 2007

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2010 - 2025
NJ State Medical License 2020 - 2025
PA State Medical License 2007 - 2010

Clinical Trials

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer Start of enrollment: 2004 Aug 01
Completed
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2013 Oct 15
Completed
Phase 1
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients Start of enrollment: 2014 Jul 01
Completed
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Start of enrollment: 2017 Mar 01
Completed
Phase 1, Phase 2
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Start of enrollment: 2018 Jun 12
Active, not recruiting
Phase 1
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Start of enrollment: 2019 Jan 17
Active, not recruiting
Phase 1
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2020 Dec 28
Recruiting
Phase 3
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Start of enrollment: 2020 May 28
Recruiting
Phase 2
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Sep 30
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...
D'Aiello, A., Owen, D. H., Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E Gray, Thomas J Dilling, Joel...> ;Journal of Thoracic Oncology. 2024 Jan 24
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced-mutated NSCLC after a third-generation EGFR TKI.
Tony Mok, Pasi A Jänne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Steuer, Yi-Long Wu, Ronan Fougeray, Pang-Dian Fan, Jie Meng, David W Sternberg, Stephen Esker...> ;Future Oncology. 2024 May 1
3 citations
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Deborah R Caswell, Philippe Gui, Manasi K Mayekar, Emily K Law, Oriol Pich, Chris Bailey, Jesse Boumelha, D Lucas Kerr, Collin M Blakely, Tadashi Manabe, Carlos Martin...> ;Nature Genetics. 2024 Jan 1
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.
Reiner, A., Ilica, A., Miao, E., Panageas, K., Imber, B., Sehgal, R., Saganty, R., Li, B., Riely, G., Yu, H., Young, R., Pike, L., Moss, N.> ;JTO Clinical and Research Reports. 2023 Dec 1
The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer.
Helena A Yu, Cooper, A.> ;Cancer Discovery. 2023 Nov 1
8 citations
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Fac...
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis Paz-Ares, Benjamin Besse, Paolo Biron...> ;Journal of Clinical Oncology. 2023 Dec 10
2 citations
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis.
Anna Skakodub, Henry Walch, Kathryn R Tringale, Jordan Eichholz, Brandon S Imber, Harish N Vasudevan, Bob T Li, Nelson S Moss, Kenny Kwok Hei Yu, Boris A Mueller, Simo...> ;Nature Communications. 2023 Aug 17
1 citations
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Alvaro Quintanal-Villalonga, Vidushi Durani, Amin Sabet, Esther Redin, Kenta Kawasaki, Moniquetta Shafer, Wouter R Karthaus, Samir Zaidi, Yingqian A Zhan, Parvathy Man...> ;Science Translational Medicine. 2023 Aug 2
3 citations
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M Wrangle, Ma...> ;Journal of Clinical Oncology. 2023 Sep 10
2 citations
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic-mutated NSCLC.
Helena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, Yasushi Goto, Enriqueta Felip, Martin Reck, Michele Vigliotti, Qian Dong, Frédérique Cantero, Pang-Dian Fan, Masa...> ;Future Oncology. 2023 Jun 1
3 citations
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Julia Rotow, Jyoti D Patel, Matthew P Hanley, Helena Yu, Mark Awad, Jonathan W Goldman, Hovav Nechushtan, Matthias Scheffler, Chih-Hsi S Kuo, Senthil Rajappa, Guilherm...> ;Clinical Cancer Research. 2023 Aug 15
5 citations
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Michael J Grant, Jacqueline V Aredo, Jacqueline H Starrett, Paul Stockhammer, Iris K van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J Piper-Valillo, Zofia Piotrows...> ;Clinical Cancer Research. 2023 Jun 1
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
Arielle Elkrief, Alex Makhnin, Khadeja A Moses, Linda S Ahn, Isabel R Preeshagul, Afsheen N Iqbal, Sara A Hayes, Andrew J Plodkowski, Paul K Paik, Marc Ladanyi, Mark G...> ;Clinical Cancer Research. 2023 Apr 14
24 citations
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
Noura J Choudhury, Antonio Marra, Jane S Y Sui, Jessica Flynn, Soo-Ryum Yang, Christina J Falcon, Pier Selenica, Adam J Schoenfeld, Natasha Rekhtman, Daniel Gomez, Mic...> ;Journal of Thoracic Oncology. 2023 Apr 1
Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.
Harry B Lengel, Junting Zheng, Kay See Tan, Corinne C Liu, Bernard J Park, Gaetano Rocco, Prasad S Adusumilli, Daniela Molena, Helena A Yu, Gregory J Riely, Manjit S B...> ;The Journal of Thoracic and Cardiovascular Surgery. 2023 May 1
39 citations
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Paul K Paik, Jamie E Chaft, Gowtham Jayakumaran, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Mar...> ;Nature Medicine. 2022 Nov 1
29 citations
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Ryan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, Lecia V Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, W...> ;Cancer Discovery. 2023 Jan 9
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Kamrine E Poels, Adam J Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O McDonald, Weiwei ...> ;Nature Communications. 2022 Sep 23
14 citations
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
P Selenica, A Marra, N J Choudhury, A Gazzo, C J Falcon, J Patel, X Pei, Y Zhu, C K Y Ng, M Curry, G Heller, Y-K Zhang, M F Berger, M Ladanyi, C M Rudin, S Chandarlapa...> ;Annals of Oncology. 2022 Dec 1
4 citations
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Recepto...
Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J Schoenfeld, Helena A Yu, Gregory J Riely, Shinichi Toyooka, Christine M Lovly, Paul P...> ;JCO Precision Oncology. 2022 Aug 1
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
Arielle Elkrief, Helena Yu> ;The Lancet. Oncology. 2022 Sep 1
33 citations
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.
Jonathan T Yang, N Ari Wijetunga, Elena Pentsova, Suzanne Wolden, Robert J Young, Denise Correa, Zhigang Zhang, Junting Zheng, Alexa Steckler, Weronika Bucwinska, Ashl...> ;Journal of Clinical Oncology. 2022 Nov 20
11 citations
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Christopher A Febres-Aldana, Jason C Chang, Ryan Ptashkin, Yuhan Wang, Erika Gedvilaite, Marina K Baine, William D Travis, Katia Ventura, Francis Bodd, Helena A Yu, Al...> ;Clinical Cancer Research. 2022 Nov 1
13 citations
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
A J Piper-Vallillo, Julia K Rotow, Jacqueline V Aredo, Khvaramze Shaverdashvili, Jia Luo, Jennifer W Carlisle, Hatim Husain, Alona Muzikansky, Rebecca S Heist, Deepa R...> ;JTO Clinical and Research Reports. 2022 Jun 1
Join now to see all

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR Inhibitor
Alexander I Spira, Helena A Yu, Clinical Lung Cancer
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
2019 ASCO Annual Meeting - 6/1/2019
Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018

Press Mentions

Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory CommitteeApril 26th, 2023
Dissolving Knowledge Gaps Regarding EGFR Exon 20 Insertion-Mutant NSCLCJuly 6th, 2022
'Brutal, Relentless' Lung Cancer Kills Dustin Diamond: What Are the Symptoms?February 2nd, 2021
Join now to see all

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey